News and Announcements
Horizon 3 Welcomes Dr.Tam Nguyen As Part of the Investment Committee
- Published December 15, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“Horizon 3 Biotech is excited to announce the addition of Dr.Tam Nguyen to our Investment Committee. Tam is a Non-Executive Director and Deputy Director of Research with over 15 years of board level experience across not for profit, healthcare and aged care sectors. He has over 22 years of working in the healthcare, health & medical research environment including tertiary teaching hospitals and medical research institutes.
Tam holds senior executive role with strategic and operational responsibilities in research business development, research innovation and commercialisation and research strategy. He consults and speaks on a broad range of topics including industry collaboration (in the Medtech and Pharma Sectors), Digital Health, Digital Transformation and the application of AI in healthcare.
Tam is well known in Australian clinical and commercial circles and his US network is also extensive. Tam works closely with Federal and State departments promoting Australia as the destination to conduct clinical trials. Tam is active with a number of professional bodies including AusBiotech, ARCS and the Society for Clinical Research Sites (SCRS).
Tam is a graduate of the VC Catalyst Program from the Wade Institute (inaugural cohort) and was on short-term secondment with Brandon Capital Partners, one of the leading Seed and Venture Capital firms in Australia.
Tam has a PhD in Biomechanics/Orthopaedic research and MBA in general management and strategy. He holds academic appointments with Melbourne Medical School and Monash Medical School and numerous fellowship appointments.
We’re looking forward to welcoming Tam to the Investment team, and we are confident he will significantly strengthen Horizon 3’s ability to invest to improve lives globally.”
About the Company
Horizon 3 Biotech Fund is an unlisted unit trust allowing Wholesale Investors to invest in up to 10 companies that are advancing leading edge technologies in therapeutics, medical devices, diagnostics, and digital health.
We are an Australian-based venture capital fund investing in private and public life sciences companies both here in Australia and globally. We are led by a senior team of Life Sciences professionals with deep experience in VC biotech funds management, R&D innovation, clinical trials, and commercialisation in the Pharma and Life Sciences sector.
- The Biotech sector is booming and we offer diversification into a high growth sector
- We invest in later-stage public and private companies across drugs, devices, diagnostics and digital health with a 3-5 year investment time horizon.
- We target a 20%+ IRR and make a positive contribution to society
Company Updates
Accessing Private Equity Opportunities at Emergence 2025
Explore the five trends redefining private equity in 2025, from wealth transitions to the rise of search funds. Join industry leaders at Emergence 2025 to gain exclusive insights and refine your investment strategies.
Why Are Fewer Companies Going Public?
The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.
A Message to Founders: A Shared Journey to 2025 – A Once in a Generation Opportunity
As we close this challenging year, let’s reflect on the resilience, lessons, and growth that brought us here. Founders, 2025 is your golden opportunity to innovate, scale, and thrive. Set your strategy, rest, and prepare to sprint into a year of unparalleled possibilities.
Backed By Leading Investment Groups and Family Offices
